Takeda’s Febuxostat Gets U.S. FDA Advisory Committee Nod for Gout; Cardio Risk Remains A Concern
This article was originally published in PharmAsia News
Executive Summary
A U.S. FDA advisory committee voted in favor of approving Takeda's gout therapy febuxostat during a Nov. 24 meeting, but strongly encouraged the agency to use its post-approval authorities to further explore a potential cardiovascular signal detected in clinical trials
You may also be interested in...
U.S. FDA Clears Takeda Uloric For Gout Indication
Despite concerns about cardiac safety, U.S. FDA approved Takeda's Uloric (febuxostat) for the chronic management of hyperuricemia in patients with gout Feb. 13. The approval marks the first new FDA-approved treatment for gout in more than 40 years
U.S. FDA Clears Takeda Uloric For Gout Indication
Despite concerns about cardiac safety, U.S. FDA approved Takeda's Uloric (febuxostat) for the chronic management of hyperuricemia in patients with gout Feb. 13. The approval marks the first new FDA-approved treatment for gout in more than 40 years
Takeda Readying To Launch Acid Reflux Med Kapidex Within A Month
Japanese drug maker looks to dexlansoprazole to help offset loses when Prevacid and anti-diabetic Actos go off patent this year.